VANCOUVER, British Columbia, Oct. 28 /PRNewswire-FirstCall/ -- ProtoKinetix Inc. (OTC Bulletin Board: PKTX), a biotech company focused on the research, development and commercialization of patented anti-aging glycopeptides (AAGPs(TM)), announced today that OTC Financial Network (OTCFN), a division of National Financial Communications Corp. (NFC), has issued a corporate profile on the Company. The OTCFN Report includes details on the ProtoKinetix technology platform, its multiple commercial applications, global target markets and management team. Interested parties can download the report at http://www.otcfn.com/pktx/pktx-report.pdf.
"Dr. Castelot-Deliencourt, chief scientist for ProtoKinetix, has achieved what was previously thought to be the impossible. She created a synthetic version of AFGP (Anti-Freeze Glycoprotein), a naturally occurring compound that enables cell survival in freezing temperatures. Her lab-created version is the industry's first stable, non-toxic and bioactive compound, even at low concentrations. Patented and trademarked by ProtoKinetix as AAGPs(TM), this revolutionary technology and its derivatives have shown to increase cellular health, survival and seem to have anti-inflammatory properties," said Geoffrey Eiten, publisher of the OTCFN Report.
"This year, ProtoKinetix entered its exciting commercial development phase, establishing partnerships with skin care manufacturers, and umbilical cord blood and health care companies to research and develop life-enhancing applications of AAGP(TM). The Company's goal is to begin generating recurring licensing revenues and royalty fees in 2009, and to increase shareholder value over the long-term," concluded Eiten.
ProtoKinetix, Inc. is a biotechnology company that has developed and
patented a family of synthetic anti-aging glycopeptides (AAGP(TM)) for
medicine and the biotechnology
|SOURCE ProtoKinetix Inc.|
Copyright©2008 PR Newswire.
All rights reserved